1. Signaling Pathways
  2. GPCR/G Protein
    Neuronal Signaling
  3. Dopamine Receptor
  4. Dopamine Receptor Isoform

Dopamine Receptor


Dopamine Receptor Related Products (230):

Cat. No. Product Name Effect Purity
  • HY-17366
    Clozapine N-oxide
    Antagonist 99.98%
    Clozapine N-oxide is a major metabolite of Clozapine and a human muscarinic designer receptors (DREADDs) agonist.
  • HY-15608
    MPTP hydrochloride
    MPTP hydrochloride is a brain penetrant dopamine neurotoxin, inducing Parkinson’s Disease.
  • HY-17366A
    Clozapine N-oxide dihydrochloride
    Antagonist 98.17%
    Clozapine N-oxide dihydrochloride is a major metabolite of Clozapine and a human muscarinic designer receptors (DREADDs) agonist.
  • HY-12520A
    SKF 38393 hydrochloride
    Agonist 99.44%
    SKF 38393 hydrochloride is a selective agonist of the dopamine D1 receptor (D1DR) with an IC50 of 110 nM.
  • HY-14538
    Antagonist 99.77%
    Haloperidol is a potent dopamine D2 receptor antagonist, widely used as an antipsychotic.
  • HY-14541
    Antagonist 99.89%
    Olanzapine (LY170053) is a selective, orally active monoaminergic antagonist with high affinity binding to serotonin H1, 5HT2A/2C, 5HT3, 5HT6 (Ki=7, 4, 11, 57, and 5 nM, respectively), dopamine D1-4 (Ki=11 to 31 nM), muscarinic M1-5 (Ki=1.9-25 nM), and adrenergic α1 receptor (Ki=19 nM).
  • HY-A0081
    Fluphenazine dihydrochloride
    Inhibitor 99.27%
    Fluphenazine dihydrochloride is a phenothiazine-class D1DR and D2DR inhibitor; used to deliver Fluphenazine to biological systems in studies probing the effects and metabolic fates of this commonly used dopamine antagonist.
  • HY-B1019
    Antagonist 99.92%
    Sulpiride is a D2 receptor a antagonist, an atypical antipsychotic drug of the benzamide class, used mainly in the treatment of psychosis associated with schizophrenia and major depressive disorder, and sometimes used in low dosage to treat anxiety and mild depression.
  • HY-135147
    Antagonist 99.85%
    ONC206 is an analogue of TRAIL inducer ONC201.
  • HY-10435A
    SKF-82958 hydrobromide
    Agonist 99.59%
    SKF-82958 ((±)-SKF 82958) hydrobromide is a dopamine D1 receptor full agonist (K0.5=4 nM), displays selective for D1 over D2 receptors (K0.5=73 nM).
  • HY-70081A
    Sumanirole maleate
    Agonist ≥99.0%
    Sumanirole maleate (U-95666E; PNU-95666E) is a highly selective D2 receptor full agonist with an ED50 of about 46 nM.
  • HY-10684
    Antagonist 99.77%
    Pridopidine, a dopamine (DA) stabilizer, acts as a low affinity dopamine D2 receptor (D2R) antagonist.
  • HY-B0735A
    Fenoldopam mesylate
    Agonist 99.86%
    Fenoldopam mesylate (SKF-82526) is a D1 receptor agonist and a novel lysine-specific demethylase 1 (LSD1) inhibitor (IC50=0.8974 μM).
  • HY-17355
    Pramipexole dihydrochloride
    Agonist ≥98.0%
    Pramipexole dihydrochloride is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively.
  • HY-B1752A
    Quinpirole Hydrochloride
    Agonist 99.52%
    Quinpirole Hydrochloride ((-)-LY 171555) is a high-affinity agonist of dopamine D2/D3 receptor.
  • HY-128770
    Agonist 99.81%
    LY3154207 is a potent, subtype selective, and orally available human dopamine D1 receptor positive allosteric modulator (PAM) with minimal allosteric agonist activity (EC50=3 nM).
  • HY-B1693
    Antagonist 99.98%
    Levomepromazine (Methotrimeprazine) is an orally available neuroleptic agent, which is commonly used to relieve nausea and vomiting in palliative care settings.
  • HY-21098A
    PD-168077 maleate
    Agonist 98.74%
    PD-168077 maleate is a selective dopamine D4 receptor agonist, with a Ki of 9 nM.
  • HY-101348
    Antagonist ≥99.0%
    L-741626 is a selective D2 dopamine receptor antagonist, with the Ki values of 2.4, 100 and 220 nM for human D2, D3 and D4 receptors respectively.
  • HY-101299B
    Dihydrexidine hydrochloride
    Agonist 99.21%
    Dihydrexidine hydrochloride (DAR-0100 hydrochloride) is a high potent, selective and full efficacy D1-like dopamine receptor (D1/D5) agonist, with an IC50 of 10 nM for D1 receptor.